Cannabinoids and Neuroprotection
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 24 (1-3) , 029-052
- https://doi.org/10.1385/mn:24:1-3:029
Abstract
Cannabinoid compounds are endowed with pharmacological properties that make them interesting candidates for therapeutic development. These properties have been known since antiquity. However, in the last decade extremely important advances in the understanding of the physiology, pharmacology, and molecular biology of the cannabinoid system have given this field of research fresh impetus and have renewed the interest in the possible clinical exploitation of these compounds. In the present review we summarize the effects elicited, at the cellular level, by cannabinoids acting through receptor-dependent and receptor-independent mechanisms. These data suggest different ways by which cannabinoids may act as neuroprotective agents (prevention of excitotoxicity by inhibition of glutamate release, antioxidant effects, anti-inflammatory actions, etc.). The experimental evidence supporting these hypotheses are presented and discussed with regard to both preclinical and clinical studies in disease states such as cerebral ischemia, brain trauma, and Multiple Sclerosis.Keywords
This publication has 98 references indexed in Scilit:
- Interleukin‐8, a chemotactic and inflammatory cytokinePublished by Wiley ,2002
- SR141716A, a potent and selective antagonist of the brain cannabinoid receptorPublished by Wiley ,2001
- Anandamide suppresses nitric oxide and TNF-α responses to Theilerʼs virus or endotoxin in astrocytesNeuroReport, 1997
- Paradoxical action of the cannabinoid WIN 55,212‐2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slicesBritish Journal of Pharmacology, 1997
- Cannabinoid Receptors CB1 and CB2: A Characterization of Expression and Adenylate Cyclase Modulation within the Immune SystemToxicology and Applied Pharmacology, 1997
- HU-211, a Novel Noncompetitive N -Methyl- d- Aspartate Antagonist, Improves Neurological Deficit and Reduces Infarct Volume After Reversible Focal Cerebral Ischemia in the RatStroke, 1995
- The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein couplingFEBS Letters, 1995
- Molecular characterization of a peripheral receptor for cannabinoidsNature, 1993
- Enantiomeric cannabinoids: stereospecificity of psychotropic activityCellular and Molecular Life Sciences, 1988
- Treatment of Human Spasticity with Δ9‐TetrahydrocannabinolThe Journal of Clinical Pharmacology, 1981